VOL: 101, ISSUE: 27, PAGE NO: 31Generic and proprietary names
Generic and proprietary names
- Didronel PMO.
- Didronel PMO contains disodium etidronate and calcium carbonate.
- Disodium etidronate decreases the rate of bone turnover and calcium carbonate increases calcium content.
- Bisphosphonate and other drugs affecting bone metabolism.
- Treatment of osteoporosis.
- Prevention of bone loss in postmenopausal women.
- Prevention and treatment of corticosteroid-induced osteoporosis.
- Moderate to severe renal impairment.
- Renal impairment.
- Disturbances of the gut such as diarrhoea, constipation, nausea, vomiting or abdominal pain.
- Exacerbation of asthma.
- Rash or itching.
- Blood disorders.
- Absorption reduced with calcium salts or calcium-containing products such as milk or other dairy produce.
- May reduce absorption of tetracycline-type antibiotics.
- Vitamin D increases the absorption of calcium.
- If the amount of calcium in the blood becomes too high, it may enhance the effect of digoxin or other cardiac glycosides.
- The two elements of Didronel PMO are taken as a 90-day cyclical regimen. The disodium etidronate tablets are taken for the first 14 days of the treatment cycle, followed by the calcium carbonate tablets for 76 days.
- Calcium tablets are effervescent.
- This medicine contains the colouring sunset yellow (E110), which can cause an allergic-type reaction.
- The disodium etidronate tablets should be taken with water on an empty stomach.
- The calcium carbonate tablets should be dissolved in water before taking.
- Patients should report any sudden onset of unexplained pain or restricted mobility.
- Continuous high-dose use of disodium etidronate is not recommended as it can impair bone mineralisation leading to increased risk of fractures.
- Calcium levels in blood and urine should be monitored in people with kidney disease.
- The therapeutic response should be evaluated.
Nurses should refer to manufacturer's summary of product characteristics and to appropriate local guidelines.